TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3805752
Drug: Leukotriene D4
Normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene D4 (LTD4) at doses of 0.2‐200 pmol
Study: 3805752
Drug: Leukotriene D4
Normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene D4 (LTD4) injections
Study: 7705096
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing norethindrone acetate/ethinyl estradiol
Study: 10584982
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IvIg) at a concentration of 10 mg/mL
Study: 26731191
Drug: Cotrimoxazole (CTX)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole (CTX) discontinuation
Study: 10749297
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol administered three times weekly (G-3/w)
Study: 10749297
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol administered two times weekly (G-2/w)
Study: 17328806
Drug: Amodiaquine plus
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine plus artesunate (4 mg/kg/day x 3 d)
Study: 16260422
Drug: Methimazole therapy
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole therapy for Graves' hyperthyroidism
Study: 15208594
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (200 microL per nostril, 3 mg/mL, 4 times daily for 8 weeks)
Study: 1063593
Drug: Combined 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined 6-mercaptopurine and methotrexate maintenance therapy
Study: 22527794
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy (MED)
Study: 7083463
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus - 50-70 mg/m2/day over 1 h daily for 5 days (39 patients)
Study: 7083463
Drug: Infusion -
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion - 50-70 mg/m2/day as a continuous infusion for 5 days (38 patients)
Study: 1331023
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 (40 mg/day for 8 weeks)
Study: 7543597
Drug: Interviewer administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interviewer administration of the AUA symptom index
Study: 19063836
Drug: Andrographolide drop-pill
Normalized name: Andrographolide
DrugBank: Andrographolide (DB05767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographolide drop-pill (1.5 g, three times a day for 3 days)
Study: 19063836
Drug: Andrographolide tablet
Normalized name: Andrographolide
DrugBank: Andrographolide (DB05767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographolide tablet (1.5 g, three times a day for 3 days)
Study: 18040663
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (CIT)
Study: 12592245
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride 60 mg/day
Study: 18047518
Drug: CDP +
Normalized name: CDP
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDP + BPO (clindamycin phosphate 10 mg mL(‐1) + benzoyl peroxide 50 mg mL(‐1))
Study: 7743989
Drug: Rice-based ORS
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based ORS (100 ml/kg)
Study: 3516262
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy or radiation therapy as initial therapy after relapse
Study: 3516262
Drug: Weekly observation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly observation during treatment
Study: 27042750
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH) treatment for 2 years
Study: 1584314
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment
Study: 18541610
Drug: Parenteral dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Parenteral dexamethasone (single dose)
Study: 22168961
Drug: Nebulized fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized fentanyl citrate (50 mcg)
Study: 19515553
Drug: Canfosfamide (CAN)
Normalized name: Ifosfamide
DrugBank: Canfosfamide (DB04972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Canfosfamide (CAN) 1000 mg/m(2) IV q 3 weeks
Study: 31602822
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate in solution (500 mg·kg‐1 body mass)
Study: 2821643
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2 mg and 4 mg
Study: 31920008
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in EGFR-positive tumors
Study: 15772571
Drug: EPT every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPT every day (0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Study: 18094013
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy
Study: 11732147
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone
Study: 6128546
Drug: Oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral captopril
Study: 21445287
Drug: Se-enriched onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-enriched onion (50 µg/day)
Study: 23697514
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT
Study: 9919013
Drug: Lobeline HCl
Normalized name: lobeline
DrugBank: Lobeline (DB05137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeline HCl (intravenous injections in incremental doses)
Study: 31710095
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 1000 mg twice daily for 12 weeks
Study: 30528802
Drug: Intense dose-dense
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense dose-dense epirubicin, paclitaxel, cyclophosphamide (iddEPC)
Study: 21129028
Drug: Lactulose (Group-L)
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose (Group-L)
Study: 25516993
Drug: Compressed air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compressed air at a flow of 4 L/min
Study: 11384567
Drug: Pilocarpine (2%)
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine (2%) four times daily to one eye and vehicle to the other
Study: 17935515
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1%
Study: 1317643
Drug: 3-mg PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-mg PGE2 vaginal suppository
Study: 21143897
Drug: Longer hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Longer hormonal treatment
Study: 15030838
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.015 mg/kg body weight) 15 minutes before surgery
Study: 1882897
Drug: Sucralfate (Sc)
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate (Sc) 6 g/day
Study: 23963965
Drug: Bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion hydrochloride extended-release (XL) for 8 weeks
Study: 15648443
Drug: Collagen-like peptide
Normalized name: Glucagon-like peptide II
DrugBank: Glucagon-like peptide II (DB12788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-like peptide gel (3% collagen-like peptide and 1% booster molecule)
Study: 10933364
Drug: Enoximone 50
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 50 mg three times a day
Study: 12971031
Drug: Levofloxacin administered
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin administered with juice and cereal with milk
Study: 2678308
Drug: Captopril (CPT)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CPT) 50 mg + hydrochlorothiazide (HCTZ) 15 mg
Study: 26853211
Drug: National Survey
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: National Survey of Adult Oral Health (NSAOH) participants
Study: 12416945
Drug: Cardioselective β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioselective β-blocker (single dose) in patients with COPD
Study: 9101212
Drug: Nilutamide 300
Normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilutamide 300 mg/day for 1 month and 150 mg thereafter
Study: 2650586
Drug: Ketotifen capsule
Normalized name: ketotifen Oral Capsule
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen capsule
Study: 12225330
Drug: Interferon plus
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon plus ribavirin (combination therapy)
Study: 29332430
Drug: Creatine phosphate
Normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine phosphate sodium (1.0 g/100 ml 0.9% saline)
Study: 30095791
Drug: No teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No teriparatide administration (control group)
Study: 28244906
Drug: Weekly teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly teriparatide administration
Study: 12632341
Drug: Standard-dose cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose cisplatin-based chemotherapy (PEB)
Study: 10694896
Drug: 5-isosorbide mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-isosorbide mononitrate (ISMO) 20 mg
Study: 14593691
Drug: 6-month wait-list
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month wait-list condition plus treatment as usual
Study: 10599373
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies combined (hydrocolloid dressing and Betamethasone propionate cream)
Study: 27959701
Drug: High-dose crizanlizumab
Normalized name: Crizanlizumab
DrugBank: Crizanlizumab (DB15271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose crizanlizumab (5.0 mg/kg)
Study: 17943639
Drug: Desmopressin tablets
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin tablets and spray
Study: 12969204
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 30 mg/kg
Study: 12969204
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 15 mg/kg
Study: 25590178
Drug: No somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No somatostatin treatments
Study: 19308439
Drug: Radon baths
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radon baths (80 Bq/l) for 15 days
Study: 22123804
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (0.5 mg/kg every 6 hours for 72 hours, 0.5 mg/kg every 12 hours on days 4 through 6, and 0.5 mg/kg/d on days 7 through 10)
Study: 10413563
Drug: 2-week treatment
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week treatment with trihexyphenidyl
Study: 15505487
Drug: Chlorthalidone (C)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (C) 25 mg/d
Study: 7932282
Drug: Cholinergic REM
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholinergic REM induction test (CRIT) with 1.5 mg RS 86 (muscarinic agonist)
Study: 30179971
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiosulfate HYD 0.075 mg/cm
Study: 12703668
Drug: Magnesium (Mg)
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (Mg) 732 mg/day
Study: 18782641
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly
Study: 8205868
Drug: Twice-daily regimen
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily regimen A: 500 micrograms in the morning and at bedtime
Study: 16380703
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH)
Study: 24800919
Drug: 6-mercaptopurine liquid
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine liquid formulation
Study: 19784509
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 0.5% ropivacaine and PCA with 0.2% ropivacaine + fentanyl 3 microg.mL‐1
Study: 8884843
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 mg/day) for 28 days, vitamin C (2 g/day), and allopurinol (600 mg/day) for 2 days before and 1 day after CABG (Group A)
Study: 8884843
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs for 3 days (Group C)
Study: 20526194
Drug: Casopitant 50
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 50 mg + Ondansetron 4 mg
Study: 20526194
Drug: Casopitant 100
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 100 mg + Ondansetron 4 mg
Study: 10195630
Drug: Nonautoclaved vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonautoclaved vaccine
Study: 14744276
Drug: High-dose eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose eptifibatide
Study: 20196149
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) therapy at a dosage of 5 mg/kg intravenously at weeks 0, 2, 6, and every 8 weeks thereafter
Study: 18554862
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (200 mg/day)
Study: 3299763
Drug: Whole theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole theophylline tablets (Euphyllin Retard)
Study: 3299763
Drug: Halved theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halved theophylline tablets (Euphyllin Retard)
Study: 20210680
Drug: Limited-sampling strategy
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Limited-sampling strategy (LSS) combining C(max) and C(12h) after EC-MPS administration
Study: 20357371
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (all doses)
Study: 29850491
Drug: Glutamine Dipeptide
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine Dipeptide (GDP) supplementation (20 g/day for 7 days)
Study: 28950289
Drug: Glycoengineered imgatuzumab
Normalized name: Imgatuzumab
DrugBank: Imgatuzumab (DB14884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoengineered imgatuzumab (GA201; 1400 mg)
Study: 2808197
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base 500 mg qid
Study: 20800358
Drug: Fentanyl Pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl Pectin Nasal Spray (FPNS)
Study: 24681228
Drug: All HB
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All HB vaccine formulations
Study: 25146720
Drug: CHOP +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP + bortezomib chemotherapy
Study: 21482964
Drug: Low-dose multivitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose multivitamin (folic acid, vitamin B6, and vitamin B12)
Study: 20545688
Drug: Probiotic milk
Normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic milk containing Lactobacillus rhamnosus GG, L. acidophilus La‐5, and Bifidobacterium animalis subsp. lactis Bb‐12
Study: 2612535
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 8 g + cholestyramine 8 g
Study: 18299653
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 1.5 mg/kg (Group L2)
Study: 25715664
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose X-ray examination (0.211 mSv)
Study: 8833520
Drug: Implant-retained mandibular
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained mandibular overdenture (IRO)
Study: 7618972
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (clear liquid diet on the first postoperative day followed by a regular diet as tolerated)
Study: 26787182
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (Exacyl, 1.5 g i.v.) before the operation
Study: 17536942
Drug: Dual Focus
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Focus Schema Therapy (DFST)
Study: 22212885
Drug: Complex course
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex course obstacle negotiation exercise (CC)
Study: 17689624
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE), 0.625 mg and medroxyprogesterone acetate (MPA), 2.5 mg
Study: 24168259
Drug: HBIG +
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIG + recombinant HBV vaccine
Study: 26826355
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (IV OT) at doses of 0.1 IU/kg, 1 IU/kg, and 5 IU/kg
Study: 26826355
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (IN OT) at doses of 0.1 IU/kg, 1 IU/kg, and 5 IU/kg
Study: 22865902
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (both doses)
Study: 12736156
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (600 mg/wk for 3 weeks)
Study: 20238255
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at a dose of 0.29 IU.min(‐1)